The Vanguard Group just provided an update on share ownership of Intercept Pharmaceuticals

The Vanguard Group just filed a "Statement of acquisition of beneficial ownership", which is also known as a 13G. In the filing, it appears as though The Vanguard Group claims to own 2,828,955 shares. This represents 8.57% of Intercept Pharmaceuticals.

Please note that typos are common in SEC filings. Please verify the information reported above before acting on it.

To receive a free e-mail notification whenever Intercept Pharmaceuticals makes a similar move, sign up!

Other recent filings from the company include the following:

Intercept Pharmaceuticals's Chief Qual. Officer & SVP Ops. just disposed of 2,455 shares - Jan. 13, 2022
Departure of Directors or Certain - Jan. 10, 2022
SVP of Intercept Pharmaceuticals just disposed of 542 shares - Jan. 4, 2022
Intercept Pharmaceuticals's Chief Human Resources Officer just disposed of 1,712 shares - Jan. 4, 2022
Intercept Pharmaceuticals's Chief Accounting Officer just disposed of 550 shares - Jan. 4, 2022

Auto Refresh

Feedback